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Abstract Microparticles, also known asmicrovesicles, found
in blood plasma, urine, and most other body fluids, may serve
as valuable biomarkers of diseases such as cardiovascular
diseases, systemic inflammatory disease, thrombosis, and can-
cer. Unfortunately, the detection and quantification of micro-
particles are hampered by the microscopic size of these
particles and their relatively low abundance in blood plasma.
The use of a combination of microfluidics and atomic force
microscopy to detect microparticles in blood plasma circum-
vents both problems. In this study, capture of a specific subset
of microparticles directly from blood plasma on antibody-
coated mica surface is demonstrated. The described method
excludes isolation and washing steps to prepare micropar-
ticles, improves the detection sensitivity, and yields the size
distribution of the captured particles. The majority of the
captured particles have a size ranging from 30 to 90 nm, which
is in good agreement with prior results obtained with micro-
particles immediately isolated from fresh plasma. Furthermore,
the qualitative shape of the size distribution of microparticles is
shown not to be affected by high-speed centrifugation or the
use of the microfluidic circuit, demonstrating the relative stable
nature of microparticles ex vivo.
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1 Introduction
Blood microparticles (MPs), also known as microvesicles, are
small particles shed from the surface of many cells upon stim-
ulation or apoptosis (Diamant et al. 2004). For a long time they
were considered as platelet dust (Wolf 1967), but now they have
been recognized to participate in important biological processes
(Cocucci et al. 2009). Examples of such processes are surface-
membrane traffic and the horizontal transfer of protein and
RNAs among neighboring cells, which are necessary for rapid
phenotype adjustments in a variety of conditions (Cocucci et al.
2009). In addition, bloodMPs have important physiological and
pathological roles in blood coagulation, inflammation and tu-
mor progression (Burnier et al. 2009; Pap et al. 2009).
Flow cytometry (FCM) and capture-based assays are com-
monly used methods to measure the number of MPs, define
their origin based on membrane antigen expression, and asses
their procoagulant features (Nomura et al. 2009; Lacroix et al.
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2010; Aupeix et al. 1997). However, these methods have their
drawbacks. FCM employs laser light which excites at 488 nm,
while MPs may have sizes far below this wavelength (Furie
and Furie 2006). Yuana et al. (2010) reported the presence of
MPs bearing CD41 antigen in plasma with sizes ranging
between 10–475 nm using atomic force microscopy (AFM).
They also found that the MP numbers detected by AFM are
1,000-fold higher than those detected by FCM. Although
capture-based assays using annexin V or MP-specific anti-
bodies allow high throughput assessment of procoagulant
features of MPs (Freyssinet 2003; Habib et al. 2008; Jy et al.
2004), these assays give no information on the size and total
number of MPs in plasma.
Electron microscopy (EM) has been used for detection of
MPs (Heijnen et al. 1999; Hughes et al. 2000; Aras et al.
2004), but this method only provides semi-quantitative in-
formation on MPs. Furthermore, sample dehydration and
vacuum procedures required in EM might affect the charac-
teristics of MPs. Recently, a promising method, nanoparticle
tracking analysis (NTA), has been applied to count MPs in
plasma (Harrison et al. 2009). This method uses a CCD
camera system that allows simultaneous tracking of multiple
particles. In the future NTA may be able to detect, count,
and size antibody-labeled MPs efficiently, thus allowing the
detection of subsets of MPs.
Not only is the analytical measurement of MPs a chal-
lenge, but also there is no golden standard yet to prepare
MPs (Yuana et al. 2011). Many studies have isolated MPs
from platelet free or platelet poor plasma by applying high
speed centrifugation or even ultracentrifugation (Piccin et al.
2007; Enjeti et al. 2007). To prevent loss and phenotypic
changes of MPs during the isolation procedure, using blood
plasma directly for MP measurement would be preferable
(Robert et al. 2009). Furthermore, the time between blood
withdrawal and the actual MP test should be as short as
possible to avoid activation of cells and coagulation pro-
cesses which may affect MP numbers and characteristics.
We propose amethod to detectMPs directly in blood plasma
by using a microfluidic flow cell and performing subsequent
analysis using AFM in liquid-tapping mode. Laminar flow
patterns within the flow cell ensure complete fluid turnover in
a controlled manner. The flow cell allows experimentation with
very small sample volumes. In this study, a detachable flow cell
was developed to enable direct contact between the fluid in the
microfluidic channel and the surface. Diluted plasma was
flown through the microfluidic channel with a controlled pres-
sure driven laminar flow andmade to be directly in contact with
anti-CD41 antibody-coated mica. MPs exposing CD41 antigen
were captured on this surface and subsequently imaged by
AFM. We employed the AFM method for MP detection pre-
viously used in the study of Yuana et al. (2010).
Clotting of the plasma and clogging of the microfluidic
channel pose a potential problem within such small volumes
and with such a sensitive detection method as AFM. These
problems have been solved by diluting plasma with either
citrate or EDTA-enriched Hepes buffer and coating the micro-
fluidics channels and the tubing of the microfluidics system.
We demonstrated that this method increases the sensitivity of
detecting specific MPs in a sample 100 to 1,000-fold. In
conclusion, the application of a flow cell allows the AFM
measurement of a specific subset of MPs directly in blood
plasma.
2 Materials and methods
2.1 Blood collection and plasma preparation
After giving their informed consent, venous blood of three
healthy volunteers is collected by using a 21-gauge needle
(BD Vacutainer, San Jose, CA) with minimal stasis. Except
for the first four ml, the blood is collected either in 1/10
volume of sodium citrate (3.2%, 0.105 M) or in K2 EDTA
(3.6 mg) using 4.5 mL BD Vacutainer tubes (Becton
Dickinson, San Jose, CA). Within 10–15 min after with-
drawal, the collected blood is centrifuged at 2,000g for
10 min at 20°C, without brake. The supernatant plasma is
carefully collected and centrifuged again at 2,000g for
10 min, 20°C, without brake, to obtain platelet poor plasma
(PPP). PPP was aliquotted in 250 μL portions, snap frozen in
liquid N2, and stored at −80°C until used. Before used, PPP is
quickly frozen-thawed at 37°C. Unless stated otherwise PPP is
used in the experiments.
2.2 Microparticles isolation
For MP isolation, 750 μL of frozen-thawed citrate PPP is
centrifuged at 18,890g and 20°C for 30 min, with minimum
brake. The supernatant is removed carefully, except for 25 μL
containing the MP pellet. This pellet is resuspended in 1 mL of
Hepes buffer [10 mM Hepes (Merck, Darmstad, Germany),
137 mMNaCl (Merck), 4 mMKCl (Merck), 0.1 mM Pefabloc
SC (Fluka, Munich, Germany), pH 7.4], vortexed, and centri-
fuged as before. The supernatant is removed, leaving a volume
of 25 μL containing the MP pellet. Subsequently, this 25 μL is
carefully diluted with 725 μL of Hepes buffer to reconstitute to
the original plasma volume (750 μL) before use in the
experiment.
2.3 Flow cell: mold fabrication
A flow cell mold is fabricated from brass. This brass is milled
so that ridges with dimensions of 10 mm×300 μm×100 μm
are created that shape the liquid channels during polymeriza-
tion. The top surface of the ridges is polished to allow viewing
through the channel from bottom to top after molding. At the
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end of the ridges, small holes are drilled and small pins are
inserted with a diameter of 1 mm and a height of about 1 mm.
2.4 Flow cell: fabrication
Polydimethylsiloxane (PDMS) flow cells are fabricated using a
Sylgard 184 kit (Dow Corning, UK). Silicone primer and
catalyst are mixed in a 10:1 ratio by weight and this mixture
is placed in a vacuum chamber for 1 h to remove air bubbles
trapped during mixing. Next, the mixture is slowly poured into
the mold and then the mold is carefully closed with a glass
plate. The mold containing the polymer solution is placed in an
oven at 70°C for 1 h. Afterwards, the glass slide with the
PDMS flow cell is released from the mold and covered with
a clean glass slide to keep the chip channel area dust-free. The
polymerized flow cell is shown in Fig. 1(a).
2.5 Flow cell: setup
The complete microfluidic setup is shown in Fig. 1(b). To
prepare the flow cell setup, a mica surface (1) is placed on a
metal support disc (2). The metal support disc is placed onto
the bottom plate of the holder device (4), in a small cavity
that closely fits the metal disc. The PDMS flow cell (3) is
placed onto the top plate with the open microfluidic chan-
nels facing down. Two pins, situated in the holder top plate
(5) align the flow cell (see the two holes next to the channels
in Fig. 1(a)) with respect to the mica surface and the holes
for the glass capillaries (7) (TSP Fused Silica Tubing, ID/OD
150/375 μm, deactivated with DPTMDS, from BGBAnalytik
Vertrieb, Germany). Then the top and bottom plate are pressed
onto each other with four screws (6). Using microscopic
inspection the screw pressure is carefully adjusted. The glass
capillary tubes are beveled to 45° before use, using a mechan-
ical grinder (Michael Deckel S0) with a disc containing dia-
mond dust. After careful rinsing with water, to remove
remaining grinding dust, the glass capillary tubes are gently
forced into the PDMS flow cell, and guided through align-
ment holes situated in the holder top plate.
2.6 Mica surface preparation for attachment of anti-human
CD41 monoclonal antibody
The surface of mica (Electron Microscopy Sciences, Washing-
ton) for MP attachment is prepared as described before (Yuana
et al. 2010) with a slight modification. Freshly cleaved mica
disks (diameter 12 mm) are overnight immersed in DMSO
containing 55% (w/v) ethanolamine at 70°C. Subsequently,
the mica surfaces are rinsed twice with dry DMSO at 70°C
and then with HPLC grade ethanol to remove the DMSO.
Next, the mica surfaces are put for 10 min into 30 mL phos-
phate buffered potassium (PBK) (10.2 g KCl, 0.97 g K2H2PO4
and 5.71 g K2HPO4 per L) (pH 7.4) previously saturated with
EGTA by adding 100 mg EGTA. The surfaces are then rinsed
with Hepes buffer, before 20 μl of 0.05 mg/mL (in Hepes
buffer) mouse anti-human CD41 antibody clone P2 (Beckman
Coulter, Fullerton, CA) is applied to the surface and incubated
for 3 h. Excess anti-CD41 is removed by washing with Hepes
buffer. Anti-CD41 antibody coated-mica surfaces are stored in
Hepes buffer until used. As a negative control, mouse IgG1
pure clone X40 (Becton Dickinson, San Jose, CA) is used
(0.05 mg/mL in Hepes buffer). The IgG1 isotype control anti-
body is allowed to incubate for 3 h on the functionalized mica
surfaces. All chemicals are purchased from Sigma Aldrich
(Munich, Germany) unless otherwise indicated.
Fig. 1 Flow cell setup. (a) Open PDMS flow cell. (b) Microfluidic
flow cell setup with schematic side view. The holder system (4,5,6) is
used to press the PDMS chip (3) onto the mica surface (1). The glass
capillary tubes (7) are guided through holes in the holder top plate (5)
to reach the connection chambers in the chip (3). The metal disc (2) is
used as a support for the mica surface. In the photo (c), the middle
channel is connected and filled with a dark blue solution; the glass
capillary tubes are bent towards the side using scotch tape. The blue
solution and scotch tape are for illustration purposes and are not used in
experiments
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Prior to the attachment of MPs antibody-coated mica
surfaces were inspected by using AFM to ensure that the
number of false spots and holes in the antibody coating was
minimized.
2.7 Attachment of microparticles
without using microfluidics
PPP (100 μL EDTA plasma) is dropped onto the mica surface
coated with IgG1 isotype control and anti-CD41 antibody
(“drop method”). To check the saturation of MPs on the
anti-CD41-coated surface, PPP is incubated on the surfaces
for 2, 30, and 60 min. Similar to what was found by Yuana
et al. (2010), 30 min incubation seemed to be sufficient. On
anti-IgG1-coated surface PPP was incubated for 60 min to
match the long exposure time on the anti-CD41 surface. The
surfaces are carefully rinsed with Hepes buffer and then
scanned by AFM to determine the number of MPs captured
on CD41- and IgG1 isotype control- coated mica surfaces.
2.8 Attachment of microparticles using microfluidic
flow cell
The open microfluidic flow cell (PDMS) is attached to a mica
surface as described above. A 1mL-syringe (BectonDickinson,
San Jose, CA, USA) is connected to a Harvard Apparatus
PicoPlus (Harvard apparatus, Holliston, MA, USA) syringe
pump and set at a constant flow speed of 0.01 mL/min. The
syringe is connected to the glass capillary tubes using Luer-
Lock Adapters and One-Piece Fittings from LabSmith (Liver-
more, CA, USA). The glass capillary tubes are gently forced
into the microfluidic chip using the beveled end.
The channels of the flow cell are rinsed with 50 μl EGTA-
enriched Hepes buffer (5 mM EGTA, 10 mM Hepes, 137 mM
NaCl, 4 mM KCl, 0.1 mM Pefabloc® SC, pH 7.4) buffer for
about 5 min. Hundred fifty μL of either EDTA plasma diluted
with EDTA-enriched Hepes buffer (20 mM EDTA (Sigma
Aldrich), 10 mM Hepes, 137 mM NaCl, 4 mM KCl, 0.1 mM
Pefabloc® SC, pH 7.4) or isolated MPs diluted with Hepes
buffer is allowed to flow through the channel in the flow cell for
about 15min total flow time. The channel is then rinsedwith 50
μL Hepes buffer (~5 min flow time). Before removal from the
flow cell, the back of the mica is carefully marked to indicate
the location of the channel in the AFM. Subsequently, the flow
cell is removed and the coated surface with the attached MPs is
rinsed with Hepes buffer and stored in Hepes buffer until
imaged by AFM. All steps are performed at room temperature
(RT).
2.9 AFM imaging
AFM imaging is performed with a Digital Instruments
Multi-mode AFM (Veeco, New York, NY, USA) using the
E scanner. Olympus cantilevers (Olympus, Tokyo, Japan)
with force constant of 2 N/m and a resonant frequency of
70 kHz are used. The liquid cell tip holder (Veeco) is rinsed
with ethanol and milli-Q water between each sample to pre-
vent contamination. Each image was scanned at 10×10 μm
and 10 images are taken at a variety of locations on the surface.
For each particle, the sum of pixel heights multiplied by the
pixel area is used to estimate a volume and subsequently to
calculate its (spherical) diameter.
3 Results
Generally, glass, polymer or similar materials are used with
microfluidics. However, the AFM cantilever must have phys-
ical access to the top of the sample and AFM requires an
atomically flat background to give the best image of the
sample. Mica is preferred surface material because it has
distinct atomically flat layers that can be easily separated for
cleaning and functionalization. As PDMS binds strongly to
mica, the mica surface can be pealed away when the PDMS is
removed, ruining the sample. In our study, the mica surface is
functionalized with antibodies to produce a hydrophilic mica
surface that cannot bind to the PDMS flow cell. Anti human-
CD41 antibody was used to coat the functionalized mica to
capture platelet MPs (PMPs) bearing CD41 surface antigen.
PMPs constitute 80–95% of blood MPs detected by FCM
(Horstman and Ahn 1999; Tesselaar et al. 2007). The IgG1
isotype control is used as a control for nonspecific binding of
MPs on anti-CD41-coated surface. A schematic overview of
the experiment is given in Fig. 2. The microfluidic setup used
in Fig. 2(b) is constructed from a PDMS flowcell (Fig. 1(b)),
attached to the mica surface by a removable holder system
(Fig. 1(b,c)) so that the flow cell can be removed from the
surface of the sample without damaging either the attached
MPs or the mica.
3.1 Application of microfluidic system to count MPs
in plasma
With microfluidics many moreMPs in the plasma sample will
have a chance to interact with the antibody-coated mica sur-
face by flowing an equal volume of plasma over a very small
active surface area in the confined volume of the microfluidic
channel. To examine this we applied the microfluidic system
and compared it with the drop method to count MPs in plasma
obtained from two healthy donors. For the microfluidic sys-
tem two samples were prepared: the first sample consists of
MPs isolated from citrate PPP, reconstituted to the original
plasma volume, and subsequently diluted 5 times with Hepes
buffer; the second sample is EDTA PPP diluted 5 times with
EDTA-enriched Hepes buffer. For the drop method undiluted
EDTA plasma is used.
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In all samples processed by themicrofluidic system, theAFM
detected MPs attached on anti-CD41-coated mica surface
(Table 1). The attachment of these MPs was specific because
there were at least two times less particles found attached on the
IgG1-coated surface compared to those on the anti-CD41-coated
surface (Table 1). This also confirms that these MPs bear CD41
surface antigen (CD41-positive MPs). Using image quantifica-
tion software we found in the samples processed by microfluidic
system that there is no significant difference in the number of
MPs attached on anti-CD41-coated surface (218, 276, 203, and
240 MPs/100 μm2). Strikingly, there were hardly any MPs
captured on anti-CD41 coated-surface by using the drop meth-
od, even after one hour incubation of plasma on the surface
(3 MPs/100 μm2 anti-CD41-coated surface and 3 MPs/
100 μm2 IgG1-coated surface, Table 1).
It has been reported in the literature (Gachet et al. 1993;
Rao et al. 1997) that when EDTA is used as anticoagulant for
blood collection, the CD41/CD61 complex on the plasma
membrane of platelets may loose their affinity for anti-CD41
and CD61 antibodies. To check this we have used FCM to
measure the binding of anti-CD61 and anti-CD41 antibodies
to platelet MPs in citrate- and EDTA-anticoagulated blood
plasma. We found that the numbers of CD41/CD61-positive
MPs in citrate and EDTA plasma are not significantly different
(see Figure S1 in the supplementary information).
Despite the fact that macroscopic clotting could be pre-
vented by diluting EDTA PPP with EDTA-enriched Hepes
buffer, we noticed in preliminary experiments that there still
was some clotting in the small confinements of the micro-
fluidic channel. In some studies it has been shown that un-
modified PDMS is not compatible with some of the blood/
plasma components and may initiate activation of the clotting
system (Belanger and Marois 2001; Whitlock et al. 1999).
Platelets adhere more strongly to the surface of unmodified
PDMS than to the modified PDMS (Khorasani and Mirzadeh
2004). Moreover, unmodified PDMS is hydrophobic and this
might induce clotting when plasma is introduced in the micro-
fluidic channel (Thorslund et al. 2005a; Thorslund et al.
2005b). To prevent this clotting in the microfluidic channels,
a solution of EGTA-enriched Hepes buffer was flowed
Fig. 2 Schematic overview of experiments. Collected blood plasma is
centrifuged twice to acquire PPP. In some experiments blood plasma
proteins are removed by use of high-speed centrifugation (a). Using an
antibody coated mica surface, a fresh PDMS chip and a holder system
a microfluidic setup is build, and the PPP is run over a small surface
area (b). Finally, mica surface is removed and imaged using AFM,
followed by automated image analysis (c)
Table 1 Comparison of microfluidic method and drop method to count
CD41-positive MPs. For the microfluidic method MPs isolated from
citrate PPP and diluted EDTA PPP of two healthy donors, D1 and D2,
were used. Isolated MPs were reconstituted to the original plasma volume
and subsequently five-fold diluted in Hepes buffer (Reconstituted isolated-
MPs D1/D2). EDTA PPP was diluted five-fold with EDTA-enriched
Hepes buffer (EDTA plasma D1/D2). For the drop method undiluted
EDTA PPP from the same healthy donors was used (EDTA plasma drop
D1/D2)
Samples Number of particles attached on
anti-CD41-coated mica
Number of particles attached on IgG1 isotype
control-coated mica
Mean SEM Mean SEM
Reconstituted isolated-MPs D1 218 51 82 22
Reconstituted isolated-MPs D2 276 50 1.7 0.6
EDTA plasma D1 203 80 70 19
EDTA plasma D2 240 40 1.8 0.04
EDTA plasma drop D1 0.15 0.09 2 0.55
EDTA plasma drop D2 3 1.5 3 1.0
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through the channel before application of the plasma. EGTA is
also known as a strong chelator of calcium ions, but it is not
known to the authors whether the EGTA also can physically
be adsorbed on the PDMS, acting to prevent clotting on the
surface of the channel, or if EGTA performs its anti-clotting
action in some other way.
3.2 Analysis of AFM images
The AFM images provide a unique challenge for image
processing. As images are generated by scanning line after
line, each neighboring line scan can have a different offset,
slope or parabolic background (Fig. 3(a,e)). This back-
ground must be dealt with for the accurate determination
of neighboring scan lines to calculate the heights and vol-
umes of the MPs correctly. The most commonly used tech-
niques involve performing linear regression on the fast scan
line and then subtracting the background estimate from each
line. This technique is frequently foiled by small, high
features on the surface, such as MPs. To overcome this
difficulty, a special technique is developed in our lab. First,
a standard linear regression subtraction is performed
(Fig. 3(b,f)). Second, Labview IMAQ is used to find all
the particles (Fig. 3(c,g)). Third, the regions containing the
particles are then removed from the background subtraction
input and the linear regression subtraction is performed
again to provide a much flatter surface (Fig. 3(d,h)). While
this is a computationally expensive task, it provides the high
precision background subtraction for the needed accurate
determination of the particle volumes.
Particle counting is performed by using the Labview
IMAQ library to determine the location of the particles.
The Imaq Count Objects 2 VI is first used to filter and
obtain a list of possible particles. This software uses a
threshold to make a binary image, and then uses the water-
shed method to count the particles. Particles that touch the
boundaries will not be counted. Additionally, all holes within
the particles are automatically filled. The lower limit of height,
width, and breadth of the particles is set to separate them from
the background. For counting, the particle must at least 3 nm
high and occupies at least 3 pixels. The particle must be larger
than 1 pixel in width or breadth. By setting this limit constant
selection rules can be applied throughout a large dataset of
AFM images.
As can be deduced from Fig. 3 the height is smaller than
the width in detected MP profiles, the MPs appear disc
shaped after binding to the surface. Using the disc radius
and height, the particle volume is estimated and converted
into an effective diameter assuming that MP have a spher-
ical shape in solution (Yuana et al. 2010). This procedure
ignores the effects of tip flattening. It seems that this does
not have a major effect on the final calculated volume of the
particles (results not shown), and only a small systematic
error exists in the volume calculations from the tip broad-
ening effect. The size distribution of the example image is
shown in Fig. 3(i).
Size distribution graphs are made to further analyze
possible differences between MPs captured from diluted
isolated MPs and from diluted EDTA plasma, to see if
high-speed centrifugation has an effect on the particle
size. No significant differences in the number and size
distribution of CD41-positive MPs was observed before
and after high-speed centrifugation (supplementary Table S1,
supplementary Figure S2). As mentioned before, we do not
need to concentrate particles using high-speed centrifugation,
however the clotting probability is strongly reduced by re-
moval of blood plasma proteins. Therefore we use purified
MPs, reconstituted to the original volume for all further
experiments.
3.3 Relationship between MP concentration and number
of MPs captured on anti-CD41-coated surface
Prior to measuring the concentration of MPs in a sample, the
dynamic range should first be established. Therefore we
used MPs isolated from frozen-thawed citrate PPP of a
healthy volunteer. Isolated MPs are first reconstituted with
Hepes buffer to reach the original plasma volume before
isolation (100%) and subsequently diluted 2 to 40-fold.
These diluted MP fractions are run through the microfluidics
system to measure the number of captured CD41-positive
MPs. Figure 4(a) shows that only at sufficiently low con-
centrations (<10%) there is a linear relationship between the
MP concentration and the number of particles attached on
the anti-CD41-coated surface. Probably because of unspec-
ified binding in the microfluidics circuit the line does not
cross the origin (0,0). At higher concentrations (>10%) the
number of MPs captured to the anti-CD41-coated surface
reaches a maximum of ~250 particles/100 μm2. This num-
ber of captured MPs is very similar to those reported in
Table 1 for the reconstituted isolated MP fraction and EDTA
plasma which are diluted 5 times before processing with the
microfluidic system.
The AFM images show that, typically, the particles are
not uniformly distributed on the surface (Fig. 3(a)). As a
result, the standard error of the mean is quite large (Fig. 4
(a)). The linear range is rather small, and it may be difficult
to find a suitable working range when samples differ as
strongly in particle counts as mentioned before (Yuana
et al. 2010). Interestingly, it is found that the size distribu-
tion does not differ significantly between different images
(Fig. 4(b)), and different dilutions (Fig. 4(c), Supplement
Table 2) of the same sample, with the exception of the
highest dilution. This sets microfluidic capture combined
with AFM imaging as the first method able to measure the
size distribution of a specific subset of MPs directly in PPP.
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4 Discussion
We report on a novel method to identify and characterize a
specific subset of MPs directly in plasma. To enable the
measurement of MPs directly in plasma, we have developed
a method that combines a microfluidic system and AFM
detection. Microfluidic channels allow blood plasma to flow
over a small surface of antibody coated mica, resulting in a
high enough surface concentration of specifically bound MPs
to detect and quantify using AFM. A much higher number of
MPs is captured from (diluted) plasma on antibody-coated
mica than without, using this microfluidic method (plasma
drop system). Further optimization of the method is required
for high-throughput measurements.
For the first time it is demonstrated that the size distribution of
CD41-positive MPs is robust against high-speed centrifugation
and dilution. However, to prevent clotting to occur, the use of
MPs isolated by means of high-speed centrifugation is advised.
Fig. 3 AFM image quantification. Original AFM image, intensity
represent height, see scale bar on the right side (a). This image is
flattened using the standard linear regression background subtraction
(b). White squares show all the particles that are found on the image
from image a (c). The background is subtracted, corrected for the
shadowed regions, and the particles are correctly sized (d). The bottom
row (e, f, g, h) shows an enlarged region of (a, b, c, d) respectively,
scale is 500 nm. The measured particles are indicated with red ellipses
(d, h). The size distribution graph of particles detected from this image
(100 μm2) is depicted (i)
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Yuana et al. (Yuana et al. 2010) have shown that
MPs isolated from fresh citrate PPP have calculated,
spherical like diameters (dsph) of ~50 nm (range 10–
475 nm). Using microfluidics we found that MPs iso-
lated from frozen-thawed citrate PPP and frozen-thawed
EDTA PPP have a similar calculated diameter (dsph) of
~45 nm. Software has been developed to automate the
measurement and counting of MPs. This results in much
more consistent results and provides faster data analysis.
By comparing the results from previous experiments by
Yuana et al. (Yuana et al. 2010) to the new automated
quantification of the same dataset we observed that the
size distribution was similar to those reported earlier
(data not shown).
There are advantages and disadvantages in using the
microfluidic system and AFM to measure MPs. In this
study we found that about 10 μL of plasma is enough
to count significant number of MPs and determine their
Fig. 4 Relationship between the
MP concentration in the sample
and the number of CD41-
positive MPs detected by AFM.
MPs isolated from
frozen-thawed citrate PPP are
diluted from 50% to 2.5%
(100% is undiluted
reconstituted-isolated MPs) in
Hepes buffer and run through the
microfluidics device (a). These
experiments were done on two
different days using the same
plasma pool of one healthy
volunteer. The size distribution
from a single dilution (3.8%) is
based on three images (b). A
normalized size distribution of
all dilutions averages is weighted
equally (c). Scale bars represent
the standard error of the mean
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size distribution. Furthermore, the microfluidic system
allows the measurement of MPs directly in plasma thus
reducing time between venepuncture and MP measure-
ment and also preventing MP loss because of washing
steps in the isolation procedure. However, the prepara-
tion of mica (modification and coating) typically takes
two days. In 20% of all cases we also dealt with
leakage from microfluidic channels during plasma injec-
tion. AFM scanning of the surface is also time-
consuming. It takes at least an hour finding a right
surface to position the AFM tip and scanning 10 images
of 100 μm2 at different locations on the surface.
Therefore, when this present method will be used as a
diagnostic tool, the throughput needs to be increased by
developing high speed AFM and automated sample han-
dling. Additionally, if fluorescent labeling can be imple-
mented efficiently, the number of particles captured should
allow optical detection of these particles by means of fluo-
rescence imaging. With the AFM technique being used for
calibration, it should be possible to fluorescently tag the
MPs to provide optical quantification of the number of
MPs on the mica surface.
5 Conclusion
In this study, it is demonstrated that by using a removable
microfluidic circuit, CD41-positive MPs can be captured
directly from diluted blood plasma, and detected by AFM.
Quantification of MPs is automated, to allow consistent and
fast quantification. Use of the microfluidic system increases
the sensitivity of MP detection considerably, leading to a
higher surface concentration of attached MPs, reducing the
AFM scanning time. Direct use of plasma as opposed to
isolated MPs shortens the pre-processing time and enables
the detection of MPs in a more natural state. Ten μL EDTA
plasma is sufficient to quantify the number and determine
the size distribution and shape of CD41-positive MPs using
microfluidics and AFM.
In future experiments the characterization of MPs from
other origins (endothelial cells, monocytes, tumor cells, etc.)
by using antigen-specific monoclonal antibodies will be
addressed. This will help in monitoring subsets of MPs that
may play a specific role in the development of certain diseases.
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